7-Methylxanthine

The MX-7 adds to Masimo’s growing portfolio of technology boards used both in its own patient monitors and also available to its OEM partners Masimo MX-7 rainbow SET Technology Board (Credit: Business Wire) Masimo (NASDAQ: MASI) announced today the release of MX-7, its latest and most advanced rainbow SET board. Designed for integration into the more than 200 multi-parameter monitors available from its more than 90 original equipment manufacturing (OEM) partners, MX-7 has the ability to support all 13 of Masimo’s SET pulse oximetry and rainbow Pulse CO-Oximetry measurements in an advanced module re-engineered to reduce power needs. The MX-7 adds to Masimo’s growing portfolio of technology boards used both in its own patient monitors and also available to its OEM partners. MX-7 builds on the current MSX low-power SET board and MX-5 rainbow board by offering more efficient power utilization, scaling its power draw based upon the combination of rainbow SET parameters being monitored to permit even longer battery run times. The MX-7 offers the full suite of Masimo’s advanced noninvasive SET and rainbow parameters. Masimo SET pulse oximetry has been clinically proven to help care teams enhance patient safety and improve patient outcomes; in fact, more than 100 independent and objective studies have shown that Masimo SET outperforms other pulse oximetry technologies during motion and low perfusion conditions, providing clinicians with increased sensitivity and specificity to make critical care decisions. SET has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates, improve CCHD screening in newborns, and, when used for continuous monitoring with Masimo Patient SafetyNet™ in post-surgical wards, reduce deaths due to opioid overdose and reduce rapid response team activations, ICU transfers, and costs. By leveraging additional wavelengths of light and breakthrough signal processing, Masimo rainbow technology allows clinicians to noninvasively and continuously monitor multiple advanced parameters that previously could only be measured using invasive techniques. Among other rainbow SET parameters, MX-7 offers: Masimo SET SpO2 (oxygen saturation) and pulse rate (PR). Noninvasive and continuous hemoglobin monitoring, SpHb, which offers real-time visibility to changes, or lack of changes, in hemoglobin between invasive samples. Continuous monitoring with SpHb monitoring as part of patient blood management (PBM) programs has been found to improve numerous outcomes.8-14 Pleth Variability Index (PVi), an index of continuous, noninvasive, dynamic indication of fluid responsiveness in select populations of mechanically ventilated adult patients. SpMet, which allows clinicians to noninvasively and continuously monitor levels of methemoglobin in the blood. SpCO, a noninvasive and continuous measurement of the carbon monoxide levels in arterial blood. Acoustic respiration rate (RRa), which uses acoustic signal processing to provide noninvasive and continuous monitoring of respiration rate for all patient populations. Plethysmographic respiration rate (RRp), which allows clinicians to seamlessly implement monitoring of this key vital sign without additional equipment by using the same SET pulse oximetry sensor that monitors oxygen saturation (SpO2). Oxygen Reserve Index (ORi), a noninvasive and continuous parameter intended to provide additional insight into a patient’s oxygen status under supplemental oxygen. Joe Kiani, Founder and CEO of Masimo, said, “The MX-7 board represents that ongoing drive for innovation and improvement, making sure that our full suite of cutting edge SET® and rainbow® measurements are universally available to all of our customers.” ORi has not received FDA 510(k) clearance and is not available for sale in the United States.